Gilead Sciences recently reported in The New England Journal of Medicine that its Phase 3 ASCENT-04/KEYNOTE-D19 trial showed ...
The Chosun Ilbo on MSN
Obesity treatments overtake Keytruda as top-selling drugs
Obesity treatments are reshaping the global pharmaceutical and biotech market landscape. Recent preliminary figures show that ...
Moderna (MRNA) stock is in focus as the mRNA-based cancer drug with Merck's (MRK) Keytruda cut melanoma recurrence/death risk ...
GlobalData on MSN
Moderna’s cancer vaccine plus Keytruda boosts RFS in melanoma study
A combination of intismeran autogene and Keytruda significantly prolonged recurrence-free survival in melanoma.
Moderna and Merck's melanoma vaccine, combined with Keytruda, could halve cancer recurrence risk, marking a breakthrough in ...
The companies have an expansive clinical program for the mRNA neoantigen therapy intismeran autogene in combination with ...
In patients with high-risk melanoma, the personalized cancer vaccine intismeran autogene and Keytruda reduced the risk of ...
Moderna pivots to infectious disease & oncology, targeting cash break-even by 2028. Click here to see why I rate MRNA stock a Buy.
Gilead has announced full results from its study of Trodelvy (sacituzumab govitecan) plus Keytruda (pembrolizumab) as a first ...
Corcept’s overall survival data “look competitive” with AbbVie’s Elahere and Merck’s blockbuster Keytruda, Truist Securities ...
With star checkpoint inhibitors like Keytruda and Opdivo now sporting subcutaneous formulations, GSK has struck a deal aimed ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results